Coherus (NASDAQ: CHRS) sets new at-the-market stock sale program
Rhea-AI Filing Summary
Coherus Oncology, Inc. (CHRS) entered into a sales agreement with Leerink Partners LLC allowing "at the market" issuances of its common stock with an aggregate offering price of up to $50.0 million. Leerink may act as sales agent or principal under a Form S-3 shelf registration declared effective on December 8, 2025.
Coherus will pay Leerink a commission of up to 3.0% of gross proceeds from each sale, and either party may terminate the agreement on ten days’ notice. Coherus intends to use any net cash proceeds for general corporate purposes, including working capital.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Aggregate offering price: $50.0 million
Sales agent commission: 3.0% of gross proceeds
Form S-3 effectiveness date: December 8, 2025
+2 more
5 metrics
Aggregate offering price
$50.0 million
Maximum total amount of common stock that may be sold under the sales agreement
Sales agent commission
3.0% of gross proceeds
Maximum commission payable to Leerink Partners LLC on each sale of Shares
Form S-3 effectiveness date
December 8, 2025
Date the shelf registration statement (File No. 333-291520) was declared effective
Sales agreement date
August 28, 2026
Date Coherus entered into the sales agreement with Leerink Partners LLC
Termination notice period
10 days
Notice period for either party to terminate the sales agreement
Key Terms
at the market offering, shelf registration statement, prospectus supplement, indemnification and contribution rights
4 terms
at the market offering financial
"deemed to be an “at the market offering” under Rule 415(a)(4)"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
shelf registration statement regulatory
"The Shares will be offered pursuant to a shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"and a prospectus supplement filed with the Commission on August 28, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
indemnification and contribution rights legal
"and provide the Agent with customary indemnification and contribution rights"
Offering Details
ATM
Offering
Offering Type
ATM
Use of Proceeds
General corporate purposes, including working capital
FAQ
What capital-raising agreement did CHRS announce on August 28, 2026?
Coherus Oncology, Inc. announced a sales agreement with Leerink Partners LLC for an "at the market" offering of its common stock, allowing it to issue and sell shares with an aggregate offering price of up to $50.0 million from time to time.
What is the maximum size of Coherus (CHRS) at-the-market program?
The at-the-market program permits Coherus to sell shares of common stock having an aggregate offering price of up to $50.0 million through or to Leerink Partners LLC, acting as agent or principal, under a previously declared effective Form S-3 shelf registration.
What commission will Coherus (CHRS) pay under the Leerink sales agreement?
Coherus will pay Leerink Partners LLC a commission of up to 3.0% of the gross proceeds from each sale of common stock effected under the at-the-market sales agreement, in addition to providing customary indemnification and contribution rights.
How will Coherus (CHRS) use net proceeds from the at-the-market offering?
Coherus intends to use any net cash proceeds it receives from sales of common stock under the at-the-market program for general corporate purposes, including working capital, as stated in connection with the sales agreement with Leerink Partners LLC.
On what registration statement is the CHRS at-the-market offering based?
The at-the-market offering of up to $50.0 million of Coherus common stock will be conducted under a Form S-3 shelf registration statement (File No. 333-291520), which was declared effective by the SEC on December 8, 2025, and a related prospectus supplement.
Can the CHRS sales agreement with Leerink be terminated?
Yes. The sales agreement between Coherus and Leerink Partners LLC may be terminated by either party at any time upon ten days’ notice to the other party, giving both Coherus and Leerink flexibility to end the at-the-market program.
AI-generated analysis. How Rhea-AI works. Not financial advice.
